Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (141-150 of 350) with videos related to

Pageof 35
Sort By:
Cancer|January 15, 1987
Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary diseaseT Terjanian, H Kantarjian, M Keating, et al.
Leukemia|April 29, 1998
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemiaJ Cortes, L Fayad, H Kantarjian, et al.
Journal of Internal Medicine|October 1, 1993
Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinomaM Wetzler, Z Estrov, M Talpaz, et al.
International Journal of Cancer|May 16, 1996
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathwaysP Kellokumpu-Lehtinen, M Talpaz, D Harris, et al.
Leukemia|November 1, 1991
Erythropoietin treatment in patients with myelodysplastic syndrome and anemiaR Kurzrock, M Talpaz, E Estey, et al.
The New England Journal of Medicine|July 15, 1999
The biology of chronic myeloid leukemiaS Faderl, M Talpaz, Z Estrov, et al.
Haematology and Blood Transfusion|January 1, 1987
Biologic agents for the management of hematological disorders: chronic myeloid leukemiaK B McCredie, M Talpaz, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemiaV Gandhi, W Plunkett, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1988
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patientsB Feinberg, R Kurzrock, M Talpaz, et al.
Cancer|October 3, 2000
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?P Kozuch, M Talpaz, S Faderl, et al.
Pageof 35

Showing results (141-150 of 350) with videos related to

Sort By:
Pageof 35
Cancer|January 15, 1987
Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary diseaseT Terjanian, H Kantarjian, M Keating, et al.
Leukemia|April 29, 1998
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemiaJ Cortes, L Fayad, H Kantarjian, et al.
Journal of Internal Medicine|October 1, 1993
Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinomaM Wetzler, Z Estrov, M Talpaz, et al.
International Journal of Cancer|May 16, 1996
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathwaysP Kellokumpu-Lehtinen, M Talpaz, D Harris, et al.
Leukemia|November 1, 1991
Erythropoietin treatment in patients with myelodysplastic syndrome and anemiaR Kurzrock, M Talpaz, E Estey, et al.
The New England Journal of Medicine|July 15, 1999
The biology of chronic myeloid leukemiaS Faderl, M Talpaz, Z Estrov, et al.
Haematology and Blood Transfusion|January 1, 1987
Biologic agents for the management of hematological disorders: chronic myeloid leukemiaK B McCredie, M Talpaz, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemiaV Gandhi, W Plunkett, H Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1988
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patientsB Feinberg, R Kurzrock, M Talpaz, et al.
Cancer|October 3, 2000
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?P Kozuch, M Talpaz, S Faderl, et al.
Pageof 35